Diagnostic Histopathology
Volume 14, Issue 11 , Pages 527-537 , November 2008

Pleomorphic sarcomas: subclassification, myogenic differentiation and prognosis

References 

  1. In:  Fletcher CDM,  Unni KK,  Mertens F editor. World Health Organization classification of tumours. Pathology and genetics of tumors of soft tissue and bone. Lyon: IARC Press; 2002;
  2. In:  Weiss SW,  Goldblum JR editor. Enzinger and Weiss’s soft tissue tumors. 5th edn.. St Louis: Mosby-Elsevier; 2008;
  3. Fletcher CD. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol. 1992;16:213–228
  4. Fletcher CDM. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006;48:3–12
  5. Dei Tos AP. Classification of pleomorphic sarcomas: where are we now?. Histopathology. 2006;48:51–62
  6. O’Brien JE, Stout AP. Malignant fibrous xanthomas. Cancer. 1964;17:1445–1455
  7. Kempson RL, Kyriakos M. Fibroxanthosarcoma of the soft tissues: a type of malignant fibrous histiocytoma. Cancer. 1972;29:961–976
  8. Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer. 1978;41:2250–2266
  9. Weiss SW. Malignant fibrous histiocytoma: a reaffirmation. Am J Surg Pathol. 1982;6:773–784
  10. Nielsen TO. Microarray analysis of sarcomas. Adv Anat Pathol. 2006;13:166–173
  11. Nakayama R, Nemoto T, Takahashi H, et al. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol. 2007;20:749–759
  12. Coindre JM, Hostein I, Maire G, et al. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histologic review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol. 2004;203:822–830
  13. Coindre JMC, Mariani O, Chibon F, et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol. 2003;16:256–262
  14. Miettinen M, Fetsch JF. Evaluation of biological potential of smooth muscle tumours. Histopathology. 2006;48:97–105
  15. Merchant W, Calonje E, Fletcher CDM. Inflammatory leiomyosarcoma: a morphological subgroup within the heterogeneous family of so- called inflammatory malignant fibrous histiocytoma. Histopathology. 1995;27:525–532
  16. Mentzel T, Calonje E, Fletcher CDM. Leiomyosarcoma with prominent osteoclast-like giant cells. Analysis of eight cases closely mimicking the so-called giant cell variant of malignant fibrous histiocytoma. Am J Surg Pathol. 1994;18:258–265
  17. Lee YF, John M, Falconer A, et al. A gene expression signature associated with metastatic outcome in human leiomyosarcomas. Cancer Res. 2004;64:7201–7204
  18. Ren B, Yu YP, Jing L, et al. Gene expression analysis of human soft tissue leiomyosarcomas. Hum Pathol. 2003;34:549–558
  19. Suehara Y, Kondo T, Fujii K, et al. Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas. Proteomics. 2006;6:4402–4409
  20. Pérot G, Derré J, Coindre JM, et al. Myocardin amplification and overexpression induce a strong smooth muscle differentiation in retroperitoneal leiomyosarcomas, in press.
  21. Furlong MA, Mentzel T, Fanburg-Smith JC. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. Mod Pathol. 2001;14:595–603
  22. Little DJ, Ballo MT, Zagars GK, et al. Adult rhabdomyosarcoma. Outcome following multimodality treatment. Cancer. 2002;95:377–388
  23. Henricks WH, Chu YC, Goldblum JR, Weiss SW. Dedifferentiated liposarcoma. A clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol. 1997;21:271–281
  24. McCormick D, Mentzel T, Beham A, Fletcher CDM. Dedifferentiated liposarcoma. Clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am J Surg Pathol. 1994;18:1213–1223
  25. Huang HY, Brennan MF, Singer S, Antonescu CR. Distant metastasis in retroperitoneal dedifferentiated liposarcoma is rare and rapidly fatal: a clinicopathological study with emphasis on the low-grade myxofibrosarcoma-like pattern as an early sign of dedifferentiation. Mod Pathol. 2005;18:976–984
  26. Bui Nguyen Binh M, Guillou L, Hostein I, et al. Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk. A study of 27 cases and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas. Am J Surg Pathol. 2007;31:1557–1566
  27. Binh MB, Sastre-Garau X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: A comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005;29:1340–1347
  28. Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization (FISH) in 200 paraffin-embedded tumor samples: utility in the differential diagnostic approach of adipocytic lesions and comparison with immunohistochemistry and real time PCR. Am J Surg Pathol. 2007;31:1476–1489
  29. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet. 2004;155:1–24
  30. Chibon F, Mariani O, Derre J, et al. ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14- q15 and 6q23 amplifications. Genes Chromosomes Cancer. 2004;40:32–37
  31. Mariani O, Brennetot C, Coindre JM, et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell. 2007;11:361–374
  32. Gebhard S, Coindre JM, Michels JJ, et al. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases. A study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2002;26:601–616
  33. Hornick JL, Bosenberg MW, Mentzel T, McMenamin ME, Oliveira AM, Fletcher CDM. Plemorphic liposarcoma. Clinicopathologic analysis of 57 cases. Am J Surg Pathol. 2004;28:1257–1267
  34. Dei Tos AP, Mentzel T, Fletcher CDM. Primary liposarcoma of the skin: a rare neoplasm with unusual high grade features. Am J Dermatopathol. 1998;20:332–338
  35. Miettinen M, Enzinger FM. Epithelioid variant of pleomorphic liposarcoma: a study of 12 cases of a distinctive variant of high-grade liposarcoma. Mod Pathol. 1999;12:722–728
  36. Merck C, Angervall L, Kindblom LG, Oden A. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta Pathol Microbiol Immunol Scand. 1983;282(Suppl):1–40
  37. Mentzel T, Calonje E, Wadden C, et al. Myxofibrosarcoma: clinicopathologic analysis of 75 cases with emphasis on the low grade variant. Am J Surg Pathol. 1996;20:391–405
  38. Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol. 2004;35:612–621
  39. 39aLin CN, Chou SC, Li CF, et al. Prognostic factors of myxofibrosarcomas: implications of margin status, tumor necrosis, and mitotic rate on survival. J Surg Oncol. 2006;93:294–30339bNascimento AF, Bertoni F, Fletcher CDM. Epithelioid variant of myxofibrosarcoma: expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases. Am J Surg Pathol. 2007;31:99–105
  40. Montgomery E, Fisher C. Myofibroblastic differentiation in malignant fibrous histiocytoma (pleomorphic myofibrosarcoma): a clinicopathological study. Histopathology. 2001;38:499–509
  41. Fisher C. Myofibrosarcoma. Virchows Arch. 2004;445:215–223
  42. Smith MEF, Fisher C, Weiss SW. Pleomorphic hyalinizing angiectatic tumor of soft parts. A low-grade neoplasm resembling neurilemoma. Am J Surg Pathol. 1996;20:21–29
  43. Folpe AL, Weiss SW. Pleomorphic hyalinizing angiectatic tumor. Analysis of 41 cases supportring evolution from a distinctive precursor lesion. Am J Surg Pathol. 2004;28:1417–1425
  44. Montgomery EA, Devaney KO, Giordano TJ, Weiss SW. Inflammatory myxohyaline tumor of distal extremities with virocyte or Reed-Sternberg-like cells: a distinctive lesion with features simulating inflammatory conditions, Hodgkin’s disease, and various sarcomas. Mod Pathol. 1998;11:384–391
  45. Meis-Kindblom JM, Kindblom LG. Acral myxoinflammatory fibroblastic sarcoma: a low-grade tumor of the hands and feet. Am J Surg Pathol. 1998;22:911–924
  46. Fletcher CD, Gustafson P, Rydholm A, et al. Clinicopathologic re- evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol. 2001;19:3045–3050
  47. Deyrup AT, Haydon RC, Huo D, et al. Myoid differentiation and prognosis in adult pleomorphic sarcomas of the extremity: an analysis of 92 cases. Cancer. 2003;98:805–813

PII: S1756-2317(08)00150-3

doi: 10.1016/j.mpdhp.2008.08.002

Diagnostic Histopathology
Volume 14, Issue 11 , Pages 527-537 , November 2008

Article Tools

* Image Usage & Resolution